Cytokinetics, Inc. (NASDAQ:CYTK) SVP Mark A. Schlossberg Sells 10,000 Shares
Cytokinetics, Inc. (NASDAQ:CYTK) SVP Mark A. Schlossberg sold 10,000 shares of the stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $23.07, for a total transaction of $230,700.00. Following the completion of the transaction, the senior vice president now directly owns 40,000 shares of the company’s stock, valued at approximately $922,800. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
CYTK opened at $22.67 on Friday. Cytokinetics, Inc. has a one year low of $7.72 and a one year high of $29.20. The company’s 50 day simple moving average is $24.04 and its 200-day simple moving average is $17.23.
Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.16). The firm had revenue of $3.83 million for the quarter, compared to analyst estimates of $4.92 million. As a group, equities analysts anticipate that Cytokinetics, Inc. will post -2.05 EPS for the current fiscal year.
Several research firms have recently weighed in on CYTK. HC Wainwright raised their price objective on shares of Cytokinetics from $38.00 to $59.00 and gave the stock a “buy” rating in a report on Thursday, July 23rd. BidaskClub lowered shares of Cytokinetics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 14th. Cantor Fitzgerald raised their price objective on shares of Cytokinetics from $29.00 to $41.00 and gave the stock an “overweight” rating in a report on Wednesday, July 15th. Raymond James began coverage on shares of Cytokinetics in a report on Friday, July 10th. They set a “strong-buy” rating and a $39.00 price objective for the company. Finally, JMP Securities raised their price objective on shares of Cytokinetics from $23.00 to $29.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $36.50.
Cytokinetics Company Profile
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.
Read More: What is the Quick Ratio?
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.